Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Trump Trade: U.S. plans AI security order without required model tests
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- Atrium Therapeutics earns $15M development milestone payment from Bristol Myers
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says